Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 3, 2013, Pages 232-250

  Mishra, Jayshree ^a   Drummond, Joseph ^d   Quazi, Sohel H ^a   Karanki, Satya Sridhar ^a   Shaw, J J ^b   Chen, Ben ^c   Kumar, Narendra ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b 21st Century Therapeutics   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BJ Pharmacy and Peoples Pharmacy   (United States)

Author keywords

Cancer vaccines; Cellular therapies; Colon cancer; Gene therapy; Immunotherapy; Jak 3; Targeted therapy; Villin

Indexed keywords

ADENOVIRUS VECTOR; ALLYL SULFIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CELECOXIB; CURCUMIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DASATINIB; FERMENTED WHEAT GERM EXTRACT; GO Y030; JANUS KINASE; MICRORNA; NANOPARTICLE; ONCOLYTIC ADENOVIRUS; PANITUMUMAB; PARVOVIRUS VECTOR; PLANT EXTRACT; QUERCETIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSAL ATTRIBUTION; CELL THERAPY; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HUMAN; INTESTINE POLYP; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PASSIVE IMMUNIZATION; PATHOGENESIS; PHARMACOGENETICS; PHARMACOGENOMICS; POLYPECTOMY; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; RESEARCH;

EID: 84877816234     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.09.014     Document Type: Review

References (136)

1. Kaler P., Galea V., Augenlicht L., Klampfer L. Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One 2010, 5:e11700.
2. Colorectal Cancer Screening. Rockville (MD); 1998.
3. Chen M.J., Cheng Y.M., Lai P.H., Wu J.F., Hsu Y.C. In vitro biocompatibility of thermally gelling liquid mucoadhesive loaded curcuminoids in colorectal cancer chemoprevention. International Journal of Colorectal Disease 2012, 7:869-878.
4. Slattery M.L. Diet, lifestyle, and colon cancer. Seminars in Gastrointestinal Disease 2000, 11:142-146.
5. Nakaji S., Umeda T., Shimoyama T., et al. Environmental factors affect colon carcinoma and rectal carcinoma in men and women differently. International Journal of Colorectal Disease 2003, 18:481-486.
6. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. The Journal of Nutrition 2001, 131:3109S-3120S.
7. Anaya D.A., Becker N.S., Abraham N.S. Global graying, colorectal cancer and liver metastasis: new implications for surgical management. Critical Reviews in Oncology/Hematology 2011, 77:100-108.
8. Saif M.W., Chu E. Biology of colorectal cancer. Cancer Journal 2010, 16:196-201.
9. Niv Y., Goel A., Boland C.R. JC virus and colorectal cancer: a possible trigger in the chromosomal instability pathways. Current Opinion in Gastroenterology 2005, 21:85-89.
10. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
11. Burn J., Mathers J., Bishop D.T. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results in Cancer Research 2012, 191:157-183.
12. Emery J., Lucassen A., Murphy M. Common hereditary cancers and implications for primary care. Lancet 2001, 358:56-63.
13. Fearon E.R. Molecular genetics of colorectal cancer. Annual Review of Pathology 2011, 6:479-507.
14. Lievre A., Blons H., Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010, 29:3033-3043.
15. Siddiqui A., Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Annals of Surgical Oncology 2010, 17:1168-1176.
16. Baba Y., Nosho K., Shima K., et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 2010, 117:1399-1408.
17. Corvinus F.M., Orth C., Moriggl R., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555.
18. Lin L., Deangelis S., Foust E., et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Molecular Cancer 2010, 9:217-227.
19. Heidelbaugh J.J., Tortorello M. The adult well male examination. American Family Physician 2012, 85:964-971.
20. Kristjansson S.R., Nesbakken A., Jordhoy M.S., et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. Critical Reviews in Oncology/Hematology 2010, 76:208-217.
21. Marshall J.L. Managing potentially resectable metastatic colon cancer. Gastrointestinal Cancer Research 2008, 2:S23-S26.
22. Matsumura Y. Polymeric micellar delivery systems in oncology. Japanese Journal of Clinical Oncology 2008, 38:793-802.
23. Morse M.A., Hall J.R., Plate J.M. Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opinion on Biological Therapy 2009, 9:331-339.
24. de la Cruz-Merino L., Grande-Pulido E., Albero-Tamarit A., Codes-Manuel de Villena M.E. Cancer and immune response: old and new evidence for future challenges. The Oncologist 2008, 13:1246-1254.
25. Halama N., Zoernig I., Jager D. Immunotherapy for cancer - modern immunologic strategies in oncology. Deutsche Medizinische Wochenschrift 2008, 133:2105-2108.
26. Kotlan B., Umansky V., Malyguine A.M., Marincola F.M., Shurin M.R. Conference scene: immunotherapy reaches new milestones in cancer eradication. Immunotherapy 2011, 3:1131-1137.
27. Mishra J., Waters C.M., Kumar N. Molecular mechanism of interleukin-2-induced mucosal homeostasis. American Journal of Physiology: Cell Physiology 2012, 302(5):C735-C747.
28. Mocellin S., Nitti D. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Medicinal Research Reviews 2008, 28:413-444.
29. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
30. Soudja S.M., Wehbe M., Mas A., et al. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. Cancer Research 2010, 70:3515-3525.
31. Shanker A., Marincola F.M. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunology, Immunotherapy: CII 2011, 60:1061-1074.
32. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annual Review of Immunology 2000, 18:767-811.
33. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine 2007, 13:1050-1059.
34. Kruger C., Greten T.F., Korangy F. Immune based therapies in cancer. Histology and Histopathology 2007, 22:687-696.
35. van de Ven R., Reurs A.W., Wijnands P.G., et al. Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy. Cancer Immunology, Immunotherapy: CII 2012, 61:181-191.
36. Limpens J., Van Meijer M., Van Santen H.M., et al. Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative. Immunology 1991, 73:255-263.
37. Yu B., Kusmartsev S., Cheng F., et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003, 9:285-294.
38. Chaudhuri D., Suriano R., Mittelman A., Tiwari R.K. Targeting the immune system in cancer. Current Pharmaceutical Biotechnology 2009, 10:166-184.
39. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews 2008, 60:1615-1626.
40. Li Y.S., Davidson E., Reid C.N., McHale A.P. Optimising ultrasound-mediated gene transfer (sonoporation) in vitro and prolonged expression of a transgene in vivo: potential applications for gene therapy of cancer. Cancer Letters 2009, 273:62-69.
41. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Advanced Drug Delivery Reviews 2008, 60:1193-1208.
42. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Science 2008, 99:1528-1538.
43. Li Q.X., Liu G., Wong-Staal F. Oncolytic virotherapy as a personalized cancer vaccine. International Journal of Cancer: Journal International du Cancer 2008, 123:493-499.
44. Vigna E., Pacchiana G., Mazzone M., et al. " Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Research 2008, 68:9176-9183.
45. Chen L., Tang X.D., Yu S.T., et al. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice. The Journal of Pathology 2009, 217:685-692.
46. Lei N., Shen F.B., Chang J.H., et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Therapy 2009, 16:33-43.
47. Davis J.J., Wang L., Dong F., et al. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Therapy 2006, 13:720-723.
48. Su C., Na M., Chen J., et al. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Molecular Cancer Research: MCR 2008, 6:568-575.
49. Huang P., Watanabe M., Kaku H., et al. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. Cancer Gene Therapy 2008, 15:315-322.
50. Gao Y., Ng S.S., Chau D.H., et al. Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. Cancer Gene Therapy 2008, 15:723-732.
51. Zhang Q., Li Y., Shi Y., Zhang Y. HVJ envelope vector, a versatile delivery system: its development, application, and perspectives. Biochemical and Biophysical Research Communications 2008, 373:345-349.
52. Goyal A.K., Khatri K., Vyas S.P. Patents on non-viral mediated gene delivery. Recent Patents on DNA & Gene Sequences 2008, 2:44-60.
53. Dass C.R., Choong P.F. Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy. Journal of Drug Targeting 2008, 16:257-261.
54. Chu L., Gu J., Sun L., Qian Q., Qian C., Liu X. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Therapy 2008, 15:484-494.
55. Gravalos C., Cassinello J., Garcia-Alfonso P., Jimeno A. Integration of panitumumab into the treatment of colorectal cancer. Critical Reviews in Oncology/Hematology 2010, 74:16-26.
56. Rodriguez J., Viudez A., Ponz-Sarvise M., et al. Improving disease control in advanced colorectal cancer: panitumumab and cetuximab. Critical Reviews in Oncology/Hematology 2010, 74:193-202.
57. Zalcman G., Richard N., Bergot E. New biological treatments for lung cancer. Revue de Pneumologie Clinique 2007, 63:20-28.
58. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 2010, 10:317-327.
59. Houot R., Kohrt H.E., Marabelle A., Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends in Immunology 2011, 32:510-516.
60. Weng D., Song B., Durfee J., et al. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. International Journal of Cancer: Journal International du Cancer 2011, 109(8):1990-2001.
61. Iwata-Kajihara T., Sumimoto H., Kawamura N., et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. Journal of Immunology 2011, 187:27-36.
62. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
63. Figdor C.G., de Vries I.J., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: mapping the way. Nature Medicine 2004, 10:475-480.
64. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
65. Palucka A.K., Ueno H., Fay J.W., Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunological Reviews 2007, 220:129-150.
66. Kawakami Y., Fujita T., Kudo C., et al. Dendritic cell based personalized immunotherapy based on cancer antigen research. Frontiers in Bioscience: A Journal and Virtual Library 2008, 13:1952-1958.
67. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
68. Mueller T., Voigt W. Fermented wheat germ extract - nutritional supplement or anticancer drug?. Nutrition Journal 2011, 10:89.
69. Nautiyal J., Kanwar S.S., Yu Y., Majumdar A.P. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. Journal of Molecular Signaling 2011, 6:7.
70. Lin L., Liu Y., Li H., et al. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. British Journal of Cancer 2011, 105:212-220.
71. Xavier C.P., Lima C.F., Rohde M., Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemotherapy and Pharmacology 2011, 68:1449-1457.
72. Murphy E.A., Davis J.M., McClellan J.L., Carmichael M.D. Quercetin's effects on intestinal polyp multiplicity and macrophage number in the Apc(Min/+) mouse. Nutrition and Cancer 2011, 63:421-426.
73. Volate S.R., Davenport D.M., Muga S.J., Wargovich M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 2005, 26:1450-1456.
74. Altonsy M.O., Andrews S.C. Diallyl disulphide, a beneficial component of garlic oil, causes a redistribution of cell-cycle growth phases, induces apoptosis, and enhances butyrate-induced apoptosis in colorectal adenocarcinoma cells (HT-29). Nutrition and Cancer 2011, 63:1104-1113.
75. 2+ mobilization in human colon cancer cell line SW480. Archives of Toxicology 2012, 86:231-238.
76. Dhayat S., Mardin W.A., Mees S.T., Haier J. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer - a review. International Journal of Cancer: Journal International du Cancer 2011, 129:1031-1041.
77. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
78. Calin G.A., Sevignani C., Dumitru C.D., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:2999-3004.
79. Du T., Zamore P.D. microPrimer: the biogenesis and function of microRNA. Development 2005, 132:4645-4652.
80. Schwarz D.S., Hutvagner G., Du T., Xu Z., Aronin N., Zamore P.D. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115:199-208.
81. Hutvagner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297:2056-2060.
82. Martinez J., Tuschl T. RISC is a 5' phosphomonoester-producing RNA endonuclease. Genes & Development 2004, 18:975-980.
83. Asangani I.A., Rasheed S.A., Nikolova D.A., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
84. Akao Y., Nakagawa Y., Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biological & Pharmaceutical Bulletin 2006, 29:903-906.
85. Toyota M., Suzuki H., Sasaki Y., et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Research 2008, 68:4123-4132.
86. Mook O.R., Baas F., de Wissel M.B., Fluiter K. Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A. Cancer Gene Therapy 2009, 16:532-538.
87. Liu X., Yang J., Shang F., et al. Silencing GIRK4 expression in human atrial myocytes by adenovirus-delivered small hairpin RNA. Molecular Biology Reports 2009, 36:1345-1352.
88. Takahashi Y., Nishikawa M., Takakura Y. Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA targeting beta-catenin or hypoxia-inducible factor 1alpha. Journal of Controlled Release: Official Journal of the Controlled Release Society 2006, 116:90-95.
89. Chaturvedi A., Battmer K., Schaefer D., Ganser A., Eder M., Scherr M. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model. Oligonucleotides 2007, 17:22-34.
90. Judge A.D., Robbins M., Tavakoli I., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. The Journal of Clinical Investigation 2009, 119:661-673.
91. Rauschhuber C., Xu H., Salazar F.H., Marion P.L., Ehrhardt A. Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice. The Journal of Gene Medicine 2008, 10:878-889.
92. Zhu H., Zhu Y., Hu J., et al. Adenovirus-mediated small hairpin RNA targeting Bcl-XL as therapy for colon cancer. International Journal of Cancer: Journal International du Cancer 2007, 121:1366-1372.
93. Narvaiza I., Aparicio O., Vera M., et al. Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. Journal of Virology 2006, 80:12236-12247.
94. Takahashi Y., Nishikawa M., Takakura Y. In vivo siRNA delivery to tumor cells and its application to cancer gene therapy. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 2007, 127:1525-1531.
95. Yoo J.Y., Kim J.H., Kim J., et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Therapy 2008, 15:635-651.
96. Sun L., Gao H., Sarma V.J., Guo R.F., Ward P.A. Adenovirus-mediated in vivo silencing of anaphylatoxin receptor C5aR. Journal of Biomedicine & Biotechnology 2006, 2006:28945.
97. Wang L., Qi X., Shen R., Sun Y., Tuveson D.A. An shRNA silencing a non-toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell. Journal of Cellular Physiology 2009, 219:365-371.
98. He B., Reguart N., You L., et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005, 24:3054-3058.
99. Gil P.R., Parak W.J. Composite nanoparticles take aim at cancer. ACS Nano 2008, 2:2200-2205.
100. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews: Drug discovery 2008, 7:771-782.
101. Schiffelers R.M., Storm G. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. International Journal of Pharmaceutics 2008, 364:258-264.
102. Cardoso A.L., Simoes S., de Almeida L.P., et al. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. The Journal of Gene Medicine 2007, 9:170-183.
103. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. Journal of Controlled Release: Official Journal of the Controlled Release Society 2008, 129:107-116.
104. Bonnet M.E., Erbacher P., Bolcato-Bellemin A.L. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharmaceutical Research 2008, 25:2972-2982.
105. Shim M.S., Kwon Y.J. Acid-responsive linear polyethylenimine for efficient, specific, and biocompatible siRNA delivery. Bioconjugate Chemistry 2009, 20:488-499.
106. Koping-Hoggard M., Tubulekas I., Guan H., et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Therapy 2001, 8:1108-1121.
107. Tan M.L., Choong P.F., Dass C.R. Cancer, chitosan nanoparticles and catalytic nucleic acids. The Journal of Pharmacy and Pharmacology 2009, 61:3-12.
108. Kumar N., Mishra J., Narang V.S., Waters C.M. Janus kinase 3 regulates interleukin 2-induced mucosal wound repair through tyrosine phosphorylation of villin. Journal of Biological Chemistry 2007, 282:30341-30345.
109. Mishra J, Karanki SS, Kumar N. Identification of molecular switch regulating interactions of janus kinase 3 with cytoskeletal proteins. Journal of Biological Chemistry 2012, in press.
110. Rimm D.L., Holland T.E., Morrow J.S., Anderson J.M. Autoantibodies specific for villin found in patients with colon cancer and other colitides. Digestive Diseases and Sciences 1995, 40:389-395.
111. Rane S.G., Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19:5662-5679.
112. Smith M.A., Marinaki A.M., Sanderson J.D. Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics 2010, 11:421-437.
113. Lam W.K., Watkins D.N. Lung cancer: future directions. Respirology 2007, 12:471-477.
114. Chu A.J., Chou T.H., Chen B.D. Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Frontiers in Bioscience: A Journal and Virtual Library 2004, 9:2697-2713.
115. Klampfer L. Cytokines, inflammation and colon cancer. Current Cancer Drug Targets 2011, 11:451-464.
116. Hawk E.T., Viner J.L., Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Progress in Experimental Tumor Research 2003, 37:210-242.
117. Bakhle Y.S. COX-2 and cancer: a new approach to an old problem. British Journal of Pharmacology 2001, 134:1137-1150.
118. Gwyn K., Sinicrope F.A. Chemoprevention of colorectal cancer. American Journal of Gastroenterology 2002, 97:13-21.
119. Dempke W., Rie C., Grothey A., Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy?. Journal of Cancer Research and Clinical Oncology 2001, 127:411-417.
120. Prescott S.M., Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochimica et Biophysica Acta 2000, 1470:M69-M78.
121. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends in Pharmacological Sciences 2003, 24:96-102.
122. Conlin A.K., Seidman A.D. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clinical Breast Cancer 2008, 8:215-223.
123. Menard C., Martin F., Apetoh L., Bouyer F., Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunology, Immunotherapy: CII 2008, 57:1579-1587.
124. Rihova B., Kovar L., Kovar M., Hovorka O. Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics. Trends in Biotechnology 2009, 27:11-17.
125. Baxevanis C.N., Perez S.A., Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunology, Immunotherapy: CII 2009, 58:317-324.
126. Zhang T., Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunology, Immunotherapy: CII 2009, 58:475-492.
127. Ferrara T.A., Hodge J.W., Gulley J.L. Combining radiation and immunotherapy for synergistic antitumor therapy. Current Opinion in Molecular Therapeutics 2009, 11:37-42.
128. Louis C.U., Brenner M.K. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Current Pharmaceutical Design 2009, 15:424-429.
129. Grinshtein N., Ventresca M., Margl R., et al. High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. Cancer Gene Therapy 2009, 16:338-350.
130. Kiewe P., Wojtke S., Thiel E., Nagorsen D. Antiviral cellular immunity in colorectal cancer patients. Human Immunology 2009, 70:85-88.
131. Mohebtash M., Gulley J.L., Madan R.A., Ferrara T., Arlen P.M. Cancer vaccines: current directions and perspectives in prostate cancer. Current Opinion in Molecular Therapeutics 2009, 11:31-36.
132. Andersen M.H., Sorensen R.B., Schrama D., Svane I.M., Becker J.C., Thor Straten P. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunology, Immunotherapy: CII 2008, 57:1735-1743.
133. Gabrilovich D.I. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. The Lancet Oncology 2007, 8:2-3.
134. Smith B.D., Kasamon Y.L., Kowalski J., et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:338-347.
135. Koido S., Homma S., Takahara A., et al. Current immunotherapeutic approaches in pancreatic cancer. Clinical & Developmental Immunology 2011, 2011:267539.
136. Timar J., Forster-Horvath C., Lukits J., et al. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer - a multicenter phase I/II clinical trial. Laryngoscope 2003, 113:2206-2217.